Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 3/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31740975 | 0.88 | EDNRA (0.47) | EDNRASIGMAR1EDNRBSMN1; SMN2BRD4 | |
| SCHEMBL11674515 | 0.88 | EDNRA (0.47) | EDNRASIGMAR1EDNRBSMN1; SMN2BRD4 | |
| SCHEMBL11766654 | 0.81 | EDNRA (0.41) | EDNRASIGMAR1EDNRBSMN1; SMN2 | |
| SCHEMBL11548815 | 0.75 | SIGMAR1 (0.46) | SIGMAR1 | |
| SCHEMBL11547445 | 0.75 | EDNRA (0.44) | EDNRASIGMAR1EDNRB | |
| SCHEMBL29436947 | 0.69 | EDNRA (0.43) | EDNRA | |
| SCHEMBL8435497 | 0.69 | MAOA (0.41) | — | |
| SCHEMBL7912606 | 0.69 | SIGMAR1 (0.49) | SIGMAR1 | |
| SCHEMBL30504112 | 0.69 | MAOA (0.41) | — | |
| SCHEMBL30311870 | 0.69 | MAOA (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002177-A1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-01-03 | — | — | US | claimed |
| JP-H08510211-A | — | — | 1996-10-29 | — | — | JP | claimed |
| CN-1124923-A | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1996-06-19 | — | — | CN | claimed |
| EP-0699069-A4 | — | — | 1996-04-03 | — | — | EP | claimed |
| EP-0699069-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-03-06 | — | — | EP | claimed |
| WO-1994025013-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-10 | — | — | WO | claimed |
| EP-1180094-B1 | FUSED POLYCYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | disclosed |
| CN-1129428-C | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 2003-12-03 | — | — | CN | disclosed |
| US-6448260-B2 | 3-(2-CARBOXYMETHOXY-4-METHOXYPHENYL)-1-(3,4-METHYLENEDIOXY -PHENYL)-5-(PROP-1-YLOXY)-INDANE-2-CARBOXYLIC ACID AS AN ESPECIALLY PREFERRED COMPOUND; HYPOTENSIVE AGENTS; CARDIOVASCULAR, UROGENITAL AND RESPIRATORY DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-09-10 | — | — | US | disclosed |
| US-20020002177-A1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-01-03 | — | — | US | disclosed |
| US-6274737-B1 | CARDIOVASCULAR DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-08-14 | — | — | US | disclosed |
| US-6271399-B1 | METHYL 3-(3,4-METHYLENEDIOXYPHENYL)-6-(PROP-1-YLOXY)-INDANE-2-CARBOXYLATE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION | 2001-08-07 | — | — | US | disclosed |
| US-6087389-A | TREATING CARDIOVASCULAR AND RENAL DISEASES INCLUDING HYPERTENSION, ACUTE AND CHRONIC RENAL FAILURE, CYCLOSPORINE INDUCED NEPHROTOXICITY, STROKE, CEREBROVASCULAR VASOSPASM, MYOCARDIAL ISCHEMIA, ANGINA, HEART FAILURE, ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-11 | — | — | US | disclosed |
| US-5719183-A | HYPOTENSIVE AGENTS; KIDNEY DISEASES; ANTIISCHEMIC AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5719182-A | TREATING HYPERTENSION, RENAL FAILURE, CEREBROVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5716984-A | INDANE AND INDENE DERIVATIVES; TREATMENT OF CARDIOVASCULAR DISORDERS, KIDNEY DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-10 | — | — | US | disclosed |
| CN-1124923-A | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1996-06-19 | — | — | CN | disclosed |
| EP-0699069-A4 | — | — | 1996-04-03 | — | — | EP | disclosed |
| EP-0699069-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994025013-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002177-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | EDNRA 1/4885SIGMAR1 370/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.